IP Library › Patent Application 14255072
Patent Application
App. No. 14/255,072

HYR1 AS A TARGET FOR ACTIVE AND PASSIVE IMMUNIZATION AGAINST CANDIDA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/255,072
Abstract

The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.

Claims (108)

1 . A vaccine comprising a polypeptide substantially identical to a fragment of a HYR1 polypeptide.

2 . The vaccine of claim 1 , wherein said HYR1 polypeptide is

(SEQ ID NO.: 1)

  1

MKVVSNFIFTILLTLNLSAALEVVTSRIDRGGIQGFHGD

VKVHSGATWAILGTTLCSFFG

 61

GLEVEKGASLFIKSDNGPVLALNVALSTLVRPVINNGVI

SLNSKSSTSFSNFDIGGSSFT

121

NNGEIYLDSSGLVKSTAYLYAREWTNNGLIVAYQNQKAA

GNIAFGTAYQTITNNGQICLR

181

HQDFVPATKIKGTGCVTADEDTWIKLGNTILSVEPTHNF

YLKDSKSSLIVHAVSSNQTFT

241

VHGFGNGNKLGLTLPLTGNRDHFRFEYYPDTGILQLRAD

ALPQYFKIGKGYDSKLFRIVN

301

SRGLKNAVTYDGPVPNNEIPAVCLIPCTNGPSAPESESD

LNTPTTSSIETSSYSSAATES

361

SVVSESSSAVDSLTSSSLSSKSESSDVVSSTTNIESSS

TAIETTMNSESSTDAGSSSISQ

421 

SESSSTAITSSSETSSSESMSASSTTASNTSIETDSGI

VSQSESSSNALSSTEQSITSSP

481

GQSTIYVNSTVTSTITSCDENKCTEDVVTIFTTVPCS

TDCVPTTGDIPMSTSYTQRTVTS

541

TITNCDEVSCSQDVVTYTTNVPHTTVDATTTTTTST

GGDNSTGGNESGSNHGPGNGSTEG

601

SGNGSGAGSNEGSQSGPNNGSGSGSEGGSNNGSGSD

SGSNNGSGSGSNNGSGSGSTEGSE

661

GGSGSNEGSQSGSGSQPGPNEGSEGGSGSNEGSNHG

SNEGSGSGSGSGSNNGSGSGSQSG

721

SGSGSQSGSESGSNSGSNEGSNPGAGNGSNEGSG

QGSGNGSEAGSGQGSGPNNGSGSGHN

781

DGSGSGSNQGSNPGAGSGSGSESGSKAGSHSGSN

EGAKTDSIEGFHTESKPGFNTGAHTD

841 

ATVTGNSVANPVTTSTESDTTISVTVSITSYMTG

FDGKPKPFTTVDVIPVPHSMPSNTTD

901

SSSSVPTIDTNENGSSIVTGGKSILFGLIVSMVVLFM.

3 . The vaccine of claim 1 , further comprising an adjuvant.

4 . The vaccine of claim 1 , wherein said fragment of the HYR1 polypeptide is expressed in a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata , and Candida parapsilosis.

5 . The vaccine of claim 1 , wherein said fragment consists of an N-terminal region fragment of the HYR1 polypeptide.

6 . The vaccine of claim 4 , wherein said fragment is

(SEQ ID NO.: 2)

  1

TSRIDRGGIQ GFHGDVKVHS

 21

GATWAILGTT LCSFFGGLEV

 41

EKGASLFIKS DNGPVLALNV

 61

ALSTLVRPVI NNGVISLNSK

 81

SSTSFSNFDI GGSSFTNNGE

101

IYLASSGLVK STAYLYAREW

121

TNNGLIVAYQ NQKAAGNIAF

141

GTAYQTITNN GQICLRHQDF

161

VPATKIKGTG CVTADEDTWI

181

KLGNTILSVE PTHNFYLKDS

201

KSSLIVHAVS SNQTFTVHGF

221

GNGNKLGLTL PLTGNRDHFR

241

FEYYPDTGIL QLRAAALPQY

261

FKIGKGYDSK LFRIVNSRGL

281

KNAVTYDGPV PNNEIPAVCL

301

IPCTNGPSAP ESESDLNTPT

321

TSSIET.

7 . The vaccine of claim 6 , wherein said fragment is a fusion polypeptide.

8 . The vaccine of claim 7 , wherein in said fragment is fused to a heterologous leader sequence.

9 . The vaccine of claim 7 , wherein said fragment is fused to a tag or a linker sequence.

10 . The vaccine of claim 6 , wherein said tag is a histidine tag.

11 . The vaccine of claim 1 , wherein said fragment is obtained from a transformed cell.

12 . The vaccine of claim 11 , wherein said transformed cell is a transformed Saccharomyces cerevisae cell.

13 . A method of treating or preventing a candidiasis infection, said method comprising administering an immunogenic amount of a vaccine of claim 1 .

14 . The method of claim 13 , wherein said candidiasis infection is disseminated candidiasis.

15 . The method of claim 13 , wherein said administering comprises active immunization, passive immunization, or a combination thereof.

16 . A method of treating or preventing a candidiasis infection, said method comprising administering an effective amount of an isolated polypeptide substantially identical to a fragment of a HYR1 polypeptide.

17 . The method of claim 16 , wherein said fragment of the HYR1 polypeptide is expressed in a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata , and Candida parapsilosis.

18 . The method of claim 16 , wherein said fragment consists of an N-terminal region fragment of the HYR1 polypeptide.

19 . The method of claim 18 , wherein said fragment is SEQ ID NO:2.

20 . The method of claim 19 , wherein said fragment is a fusion polypeptide.

21 . The method of claim 20 , wherein in said fragment is fused to a heterologous leader sequence.

22 . The method of claim 21 , wherein said fragment is fused to a tag or a linker sequence.

23 . The method of claim 22 , wherein said tag is a histidine tag.

24 . The method of claim 16 , wherein said fragment is obtained from a transformed cell.

25 . The method of claim 24 , wherein said transformed cell is a transformed Saccharomyces cerevisae cell.